Evers, Stefan
F. Hoffmann-La Roche AG
2 papers on CoChatORCID 0000-0001-9587-5325
Most cited papers
- Verified
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 1,000
- Verified
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., et al. (2017) · OncoImmunology
Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers
Cited by 281
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free